Skip to main content

Table 3 Ratios of GSH/GSSG before and after treatments with BORT and its combinations with CB and OX in A2780, A2780 cisR and SKOV-3 ovarian cancer cell lines

From: Carboplatin and oxaliplatin in sequenced combination with bortezomib in ovarian tumour models

  A2780 A2780cisR SKOV-3
Control 241.32 40.2 38.00
BORT 31.3 14.7 42.56
CB + BORT (0/2 h) 78.35 13.1 38.53
CB + BORT (2/0 h) 50.27 13.8 35.70
OX + BORT (0/2 h) 71.77 39.25 38.16
OX + BORT (2/0 h) 69.97 33.31 43.74